Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) recruits the first cohort of patients for its Phase 1 intravenous clinical trial of its lead compound RECCE 327 (R327)
- The trial is an ascending dose, randomised, placebo-controlled, double-blind study evaluating the safety and pharmacokinetics of R327 in 10 healthy male subjects
- The lead compound is administered as a single dose via a one-hour IV infusion with all 80 subjects expected to be dosed by the end of H1 2022
- The first cohort will be dosed over two days starting on December 16 with the first set of safety subject data anticipated at the end of 2021
- Recce Pharmaceuticals is up 3.17 per cent to $0.98 per share at 11:47 am AEDT
Recce Pharmaceuticals (RCE) has recruited the first cohort of patients for its Phase 1 intravenous clinical trial of its lead compound RECCE 327 (R327).
The trial is an ascending dose, randomised, placebo-controlled, double-blind study evaluating the safety and pharmacokinetics of R327 in 10 healthy male subjects.
The trial is being conducted at Adelaide’s CMAX clinical trial facility and will enrol 80 healthy male subjects in total.
The lead compound is administered as a single dose via a one-hour IV infusion with all 80 subjects expected to be dosed by the end of H1 2022.
“We are very pleased to have the first cohort recruited for the clinical trial of R327,” CEO James Graham said.
“According to the Pew Charitable Trusts, R327 is the only clinical-stage antibiotic in the world being developed for sepsis, representing the largest unmet medical need in human health, the potential medical benefits are very significant indeed.”
The first cohort will be dosed over two days starting on December 16 with the first set of safety subject data anticipated at the end of 2021.
Recce Pharmaceuticals is up 3.17 per cent to $0.98 per share at 11:47 am AEDT.
